00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
18:19 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Patient sample, cell culture and mouse studies suggest promoting SPHK1 expression could help treat AD. In postmortem brain tissue samples from AD patients, neuron levels of SPHK1 were lower than in...
08:00 , Dec 3, 2015 |  BC Innovations  |  Targets & Mechanisms

The two faces of LTA4H

Although the enzyme LTA4H has long been considered a driver of inflammatory diseases, companies have yet to create an inhibitor that succeeds in the clinic beyond Phase II. That could be due to a secondary,...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Formyl peptide receptor-like 1 (FPRL1; FPR2) Cell culture studies suggest agonizing FPR2 in innate immune cells...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology ...
07:00 , Jul 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Inflammation ...
07:00 , Mar 20, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease ...
07:00 , Aug 19, 2002 |  BC Week In Review  |  Company News

Harvard Medical School other research news

Researchers published in Nature Medicine that mice treated with a stable analog of LXA4 showed reduced airway hyper-responsiveness and pulmonary inflammation in response to allergen than controls (p<0.05). The analog inhibited leukocyte infiltration as well...